RESUMO
Schistosoma mansoni (S. mansoni) eggs trapped in the host liver elicit a chain of oxidative processes that may be, at least in part, responsible for the pathology and progression of fibrosis associated with schistosomal hepatitis. This study was designed to assess the protective effect of the antioxidant coenzyme-Q10 (Co-Q10) against experimental S. mansoni-induced oxidative stress in the liver, and its potential role as an adjuvant to praziquantel (PZQ) therapy. The oxidative stress and overall liver function were improved under Co-Q10 therapy as evidenced by significant reduction in oxidative stress markers and preservation of antioxidant factors. Liver fibrosis was also reduced with a positive impact on liver function. Moreover, addition of Co-Q10 to PZQ therapy caused: significant reduction of liver egg load, significant improvement of the redox status, and lastly decreased liver fibrosis.
Assuntos
Hepatite/metabolismo , Hepatopatias Parasitárias/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Esquistossomose mansoni/metabolismo , Ubiquinona/farmacologia , Actinas/análise , Animais , Anti-Helmínticos/uso terapêutico , Arildialquilfosfatase/análise , Biomphalaria , Hidrolases de Éster Carboxílico/análise , Modelos Animais de Doenças , Glutationa/análise , Hepatite/tratamento farmacológico , Hepatite/parasitologia , Imuno-Histoquímica , Fígado/química , Fígado/enzimologia , Fígado/parasitologia , Fígado/patologia , Hepatopatias Parasitárias/tratamento farmacológico , Masculino , Malondialdeído/análise , Camundongos , Óxido Nítrico/análise , Contagem de Ovos de Parasitas , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Organismos Livres de Patógenos Específicos , Ubiquinona/uso terapêuticoRESUMO
Simultaneous platelet and fibrinogen survival and turnover were studied using selenomethionine (75Se) in early and late groups of schistosomal hepatic fibrosis (SHF) and in a control group. In the control group, the mean platelet survival was 11.66 +/- 1.59 days and mean platelet turnover was 20,230 +/- 5090 platelets/microliter/day. Mean fibrinogen survival was 7.3 +/- 0.60 days and fibrinogen turnover was 0.35 +/- 0.04 mg/ml/day. In the early schistosomal group, platelet survival was shortened with an increased turnover rate and normal platelet count. The presence of a structurally abnormal fibrinogen molecule in the early group may have resulted in its shortened survival, that was compensated by the liver through increasing the turnover rate. In the late group, platelet survival was shortened with no significant increase of fibrinogen turnover, while fibrinogen concentration remained normal, suggesting the presence of extrahepatic sites of fibrinogen synthesis.
Assuntos
Plaquetas/metabolismo , Fibrinogênio/metabolismo , Hepatopatias Parasitárias/metabolismo , Esquistossomose/metabolismo , Selênio , Humanos , Hepatopatias Parasitárias/sangue , Masculino , Contagem de Plaquetas , Radioisótopos , Esquistossomose/sangue , SelenometioninaRESUMO
Investigations were done to study the calcium and phosphorus metabolic changes in 35 children with hepatic bilharziasis, of whom 12 were ascitic. Thirteen normal children served as controls. Despite a normal serum level of both calcium and inorganic phosphate in the Bilharzial group, yet both were increased in urine. The mean values obtained from the ascitic fluid were 70% and 90.2% of their serum levels, respectively. The corrected creatinine clearance was significantly diminished, while PEI was significantly increased, and the % TRP significantly decreased, with still a more marked decrease in the ascitic cases. Following a phosphate lead the serum inorganic phosphate level showed a significantly more rapid lowering in both bilharzial groups, as compared to the control group. On the other hand bilharzial cases responded to the intravenous calcium load by a significant retention of calcium in the serum.